Phase 1 Clinical Trial Data Indicate IGC’s THC-based Investigational New Drug May Reduce Symptoms of Dementia in Alzheimer’s Patients
Cannabis Law Report
DECEMBER 2, 2021
(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The investigational new drug, IGC-AD1, is IGC’s proprietary Tetrahydrocannabinol (THC)-based candidate designed to treat certain symptoms of Alzheimer’s disease. The degree of the decrease varied by cohort.
Let's personalize your content